Efficacy and Safety of Rimegepant 75 Mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial (vol 17, pg 2431, 2024)

被引：0
|
作者：
Lipton, R. b
Thiry, A.
Morris, B. a
Croop, R.
机构：
来源：
JOURNAL OF PAIN RESEARCH | 2024年 / 17卷
关键词：
D O I：
10.2147/JPR.S499096
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：4085 / 4086
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Rimegepant 75 mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial
    Lipton, Richard B.
    Thiry, Alexandra
    Morris, Beth A.
    Croop, Robert
    JOURNAL OF PAIN RESEARCH, 2024, 17 : 2431 - 2441
  • [2] Efficacy, Safety, and Tolerability of Rimegepant 75 Mg, an Oral CGRP Receptor Antagonist, for the Acute Treatment of Migraine: Results from a Double-blind, Randomized, Placebo-controlled Trial, Study 301
    Lipton, R. B.
    Conway, C. M.
    Stock, E. G.
    Stock, D.
    Morris, B. A.
    McCormack, T.
    Frost, M.
    Gentile, K.
    Coric, V
    Croop, R.
    HEADACHE, 2018, 58 (08): : 1336 - 1337
  • [3] Efficacy, Safety, and Tolerability of Rimegepant 75 mg Orally Dissolving Tablet for the Acute Treatment of Migraine: Results from a Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial, Study 303
    Lipton, Richard B.
    Coric, Vladimir
    Stock, David A.
    Gosden, Ralph
    Forshaw, Micaela
    Croop, Robert
    Conway, Charlie
    CEPHALALGIA, 2019, 39 : 7 - 8
  • [4] Efficacy, Safety, and Tolerability of Rimegepant 75 Mg Orally Dissolving Tablet for the Acute Treatment of Migraine: Results from a Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial, Study 303
    Lipton, R. B.
    Coric, V
    Stock, E. G.
    Stock, D. A.
    Thiry, A. C.
    Conway, C. M.
    Dubowchik, G. M.
    Jensen, C. M.
    Gosden, R.
    Frost, M.
    Gentile, K.
    Morris, B. A.
    Forshaw, M.
    Croop, R.
    HEADACHE, 2019, 59 : 21 - 22
  • [5] Efficacy, safety, and tolerability of rimegepant 75 mg orally dissolving tablet for the acute treatment of migraine: Results from a phase 3, double-blind, randomized, placebo-controlled trial, Study 303
    Lipton, Richard B.
    Coric, Vladimir
    Stock, Elyse
    Stock, David
    Thiry, Alexandra
    Conway, Charles
    Dubowchik, Gene
    Jensen, Christopher
    Gosden, Ralph
    Frost, Marianne
    Gentile, Kimberly
    Morris, Beth
    Forshaw, Micaela
    Croop, Robert
    NEUROLOGY, 2019, 93 (05) : E532 - E532
  • [6] Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
    Croop, Robert
    Goadsby, Peter J.
    Stock, David A.
    Conway, Charles M.
    Forshaw, Micaela
    Stock, Elyse G.
    Coric, Vladimir
    Lipton, Richard B.
    LANCET, 2019, 394 (10200): : 737 - 745
  • [7] Efficacy, safety, and tolerability of rimegepant 75 mg orally disintegrating tablet for the acute treatment of migraine: Results from a phase 3, double-blind, randomized, placebo-controlled trial in adults from China and Korea
    Yu, S.
    Goodrich, R.
    HEADACHE, 2022, 62 (07): : 924 - 925
  • [8] RIMEGEPANT 75 MG, AN ORAL CALCITONIN GENE-RELATED PEPTIDE ANTAGONIST, FOR THE ACUTE TREATMENT OF MIGRAINE: TWO PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIALS
    Lipton, R. B.
    Coric, V.
    Stock, E. G.
    Stock, D. A.
    Morris, B. A.
    McCormack, T. J.
    Frost, M.
    Gentile, K.
    Jensen, C. M.
    Dubowchik, G. M.
    Conway, C. M.
    Croop, R.
    Goadsby, P. J.
    CEPHALALGIA, 2018, 38 : 140 - 141
  • [9] Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial
    Yu, Shengyuan
    Guo, Aihong
    Wang, Zhen
    Liu, Jianguang
    Tan, Ge
    Yang, Qian
    Zhang, Mingjie
    Yibulaiyin, Hasiyeti
    Chen, Huisheng
    Zhang, Yongbo
    Croop, Robert
    Sun, Yanhui
    Liu, Yu
    Zhao, Qian
    Lu, Zhihong
    JOURNAL OF HEADACHE AND PAIN, 2024, 25 (01):
  • [10] Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial
    Yu, Shengyuan
    Kim, Byung-Kun
    Guo, Aihong
    Kim, Man-Ho
    Zhang, Mingjie
    Wang, Zhen
    Liu, Jianguang
    Moon, Heui-Soo
    Tan, Ge
    Yang, Qian
    McGrath, Donnie
    Hanna, Michael
    Stock, David A.
    Gao, Yanfei
    Croop, Robert
    Lu, Zhihong
    LANCET NEUROLOGY, 2023, 22 (06): : 476 - 484
12345